Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

CAR-T cells in systemic B cell mediated autoimmune disease - CASTLE Recruiting

2024-516819-24-00 Systemic Sclerosis 9 2023-05-16
Immune-Related Rheumatological and neurological Adverse Events study. Recruiting

2024-516631-27-00 Cancer (all types) 4 2023-05-05
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN). Recruiting

2023-507233-19-00 Treatment of IgAN 10 2023-02-16
Study of efficacy and safety of LNP023 in participants with active lupus nephritis Class III-IV, +/- V Recruiting

2023-509332-26-00 Lupus Nephritis Class III-IV, +/- V 4 2023-02-16
A Trial to Evaluate EP 104GI in Adults with Eosinophilic Esophagitis (EoE) (RESOLVE) Recruiting

2024-516689-13-00 Eosinophilic esophagitis 9 2023-02-06
A Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cut… Recruiting

2023-505634-94-00 Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneo 10 2023-02-02
Efficacy of a sequential treatment strategy in Rheumatoid Arthritis. Recruiting

2022-500234-29-00 Rheumatoid Arthritis 5 2022-11-28
Early discontinuation of steroid treatment in negative FDG-PET/CT patients with idiopathic retroperitoneal fibrosis Recruiting

2024-514353-30-00 Idiopathic retroperitoneal fibrosis 6 2022-11-25
Administration of the BCL-2 antagonist, venetoclax, to promote apoptosis of HIV-infected cells and reduce the size of the HIV reservoir: An … Recruiting

2024-518873-32-00 HIV-1 disease 9 2022-10-28
DFIL2-REP - Study of the clinical and biological response to repeated administration of low-dose interleukin-2 in patients with type 1 diabe… Recruiting

2024-514043-29-00 Patient with newly diagnosed (≤ 3 months) type 1 diabet 4 2022-09-21
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoria… Recruiting

2022-500408-22-00 Plaque Psoriasis 5 2022-09-14
“A Phase II, double-blinded, placebo-controlled clinical trial to evaluate the safety and efficacy of mesenchymal cells (MSV-ALLO®) in the t… Recruiting

2024-514750-67-00 Lupus Nephritis 10 2022-09-13
Baricitinib in patients with relapsing or naïve dermatomyositis (BIRD) Recruiting

2024-511899-32-00 Dermatomyositis; Baricitinib in patients with relapsing 10 2022-08-31
A Single center, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of neoadjuvant and adjuvant Pembrolizumab on top of standa… Recruiting

2024-517535-52-00 Glioblastoma Multiforme 6 2022-08-24
A study of MK-7240/PRA023 in patients with Systemic Sclerosis Associated with Interstitial Lung Disease Recruiting

2023-509743-27-00 Systemic sclerosis associated with interstitial lung di 4 2022-04-29
Efficacy and safety of subcutaneous dupilumab for the treatment of adult participants with chronic pruritus of unknown origin (CPUO) Recruiting

2023-508879-36-00 Pruritus 5 2022-04-28
Study of the genetic, viral and immune response characteristics of a group of patients infected with the AIDS virus treated early and then s… Recruiting

2024-515419-24-00 HIV-1 positive subjects treated with effective antiretr 6 2022-04-27
TOASST Study: Taper Or Abrupt Steroid STop? Recruiting

2024-517334-18-00 Inflammatory or autoimmune disorders 6 2022-04-06
HTLP-onco-adult - A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate im… Recruiting

2024-516104-42-00 hematologic malignancies ; acute myeloid leukemias 1 2022-02-17
API-AHAI - Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a P… Recruiting

2024-513191-17-00 autoimmune hemolytic anemia 4 2022-02-03
Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva) Recruiting

2024-512082-14-00 Untreated small triple negative breast cancer 4 2021-12-06
Efficacy and Safety Study of Nipocalimab IV Infusions for Adults With Generalized Myasthenia Gravis Recruiting

2023-504152-97-00 Generalized Myasthenia Gravis 5 2021-11-26
HARBOR: Study of BLU-263 for Indolent Systemic Mastocytosis Recruiting

2024-516728-32-00 Indolent Systemic Mastocytosis and SSM 10 2021-10-29
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis an… Recruiting

2023-505825-15-00 Lupus Nephritis (LN) 4 2021-10-29